| Symbol | ORXOF |
|---|---|
| Name | OREXO AB |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | SE-751 05 Sweden P.O. Box 303 Virdings alle 22 |
| Telephone | +46 18-780 88 00 |
| Fax | — |
| — | |
| Website | http://www.orexo.com |
| Incorporation | SE |
| Incorporated On | 1995 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Ernst & Young LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Nasdaq OMX Nordic Exchange Stockholm |
| CIK | 0001585063 |
| Description | Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees to 110. Orexo is listed on Nasdaq Stockholms main list and is available as an ADR on OTCQX market (ORXOY) in the US. Additional info from OTC: |
OTCQX International symbol attribute type Security_Name was changed. Previous value: -. New value: OREXO AB SP/ADR.
Read moreOTCQX International symbol attribute type Security_Name was changed. Previous value: -. New value: OREXO AB ORD.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: OREXO AB SP/ADR.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: OREXO AB ORD.
Read more